In its announcement, Sanofi said regulatory action on sarilumab, an IL-6 antibody, could be delayed after an FDA "fill-finish" plant inspection. The agency had been set to decide by the end of this month on that anti-inflammatory drug, which bested AbbVie's megablockbuster Humira in a Phase III trial in rheumatoid arthritis. Sanofi's Q3 results are an improvement on a bruising second quarter for the French drugmaker, when it reported net income off 11% to €1.16 billion on sales that had declined by 4.3% to €8.14 billion.